$388.54 Million in Sales Expected for Amedisys Inc (NASDAQ:AMED) This Quarter
Wall Street brokerages expect Amedisys Inc (NASDAQ:AMED) to post $388.54 million in sales for the current fiscal quarter, Zacks reports. Five analysts have made estimates for Amedisys’ earnings, with the highest sales estimate coming in at $397.58 million and the lowest estimate coming in at $381.20 million. Amedisys reported sales of $361.60 million in the same quarter last year, which indicates a positive year-over-year growth rate of 7.5%. The company is scheduled to report its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Amedisys will report full-year sales of $388.54 million for the current financial year, with estimates ranging from $1.52 billion to $1.55 billion. For the next fiscal year, analysts expect that the business will post sales of $1.62 billion per share, with estimates ranging from $1.61 billion to $1.64 billion. Zacks’ sales averages are an average based on a survey of research firms that follow Amedisys.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Wednesday, July 26th. The health services provider reported $0.62 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.12. The company had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. Amedisys’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the firm posted $0.42 EPS.
A number of analysts have recently weighed in on AMED shares. Zacks Investment Research raised Amedisys from a “hold” rating to a “buy” rating and set a $59.00 price objective for the company in a research report on Monday, April 17th. Jefferies Group LLC reissued a “buy” rating and issued a $57.00 price objective on shares of Amedisys in a research report on Friday, April 28th. Mizuho raised Amedisys from a “neutral” rating to a “buy” rating and set a $65.00 price objective for the company in a research report on Wednesday, May 3rd. BidaskClub cut Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Stephens raised their price objective on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 4th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $56.50.
Amedisys (AMED) opened at 48.88 on Monday. Amedisys has a one year low of $34.58 and a one year high of $65.91. The company’s 50 day moving average price is $56.08 and its 200-day moving average price is $54.19. The stock has a market capitalization of $1.66 billion, a PE ratio of 41.78 and a beta of 0.89.
In other news, Director Bruce D. Perkins purchased 500 shares of the stock in a transaction on Thursday, May 25th. The stock was bought at an average price of $59.69 per share, with a total value of $29,845.00. Following the transaction, the director now owns 13,331 shares in the company, valued at approximately $795,727.39. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bruce D. Perkins purchased 2,000 shares of the stock in a transaction on Thursday, August 3rd. The shares were purchased at an average cost of $46.60 per share, with a total value of $93,200.00. Following the transaction, the director now owns 15,825 shares in the company, valued at approximately $737,445. The disclosure for this purchase can be found here. Insiders own 2.80% of the company’s stock.
A number of hedge funds have recently modified their holdings of the company. OxFORD Asset Management LLP purchased a new stake in shares of Amedisys during the second quarter worth approximately $2,250,000. Dimensional Fund Advisors LP boosted its stake in shares of Amedisys by 0.7% in the second quarter. Dimensional Fund Advisors LP now owns 1,124,943 shares of the health services provider’s stock worth $70,658,000 after buying an additional 7,963 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Amedisys by 38.3% in the second quarter. Parametric Portfolio Associates LLC now owns 101,560 shares of the health services provider’s stock worth $6,379,000 after buying an additional 28,133 shares in the last quarter. Suntrust Banks Inc. boosted its stake in shares of Amedisys by 4.3% in the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock worth $358,000 after buying an additional 237 shares in the last quarter. Finally, Sawgrass Asset Management LLC purchased a new stake in shares of Amedisys during the second quarter worth approximately $1,048,000. 98.54% of the stock is owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.